

# **RESEARCH REPOSITORY**

# This is the author's final version of the work, as accepted for publication following peer review but without the publisher's layout or pagination. The definitive version is available at:

https://doi.org/10.1016/j.vetmic.2019.108408

Murphy, R.J.T., Ramsay, J.P., Lee, Y.T., Pang, S., O'Dea, M.A., Pearson, J.C., Axon, J.E., Raby, E., Abdulgader, S.M., Whitelaw, A. and Coombs, G.W. (2019) Multiple introductions of methicillin-resistant Staphylococcus aureus ST612 into Western Australia associated with both human and equine reservoirs. International Journal of Antimicrobial Agents

https://researchrepository.murdoch.edu.au/id/eprint/50824

Copyright: © 2019 Elsevier B.V. It is posted here for your personal use. No further distribution is permitted.

Multiple introductions of methicillin-resistant Staphylococcus aureus ST612 into Western Australia associated with both human and equine reservoirs

Riley JT Murphy, Joshua P Ramsay, Yung T Lee, Stanley Pang, Mark A O'Dea, Julie C Pearson, Jane E Axon, Edward Raby, Shima M Abdulgader, Andrew Whitelaw, Geoffrey W Coombs

 PII:
 S0924-8579(19)30240-7

 DOI:
 https://doi.org/10.1016/j.ijantimicag.2019.08.022

 Reference:
 ANTAGE 5793




To appear in: International Journal of Antimicrobial Agents

Received date:27 May 2019Accepted date:24 August 2019

Please cite this article as: Riley JT Murphy, Joshua P Ramsay, Yung T Lee, Stanley Pang, Mark A O'Dea, Julie C Pearson, Jane E Axon, Edward Raby, Shima M Abdulgader, Andrew Whitelaw, Geoffrey W Coombs, Multiple introductions of methicillin-resistant Staphylo-coccus aureus ST612 into Western Australia associated with both human and equine reservoirs, *International Journal of Antimicrobial Agents* (2019), doi: https://doi.org/10.1016/j.ijantimicag.2019.08.022

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier B.V.



Highlights

- ST612 MRSA isolates in Australia form distinct equine/veterinarian-associated and human-associated clades.
- Bacteremia-causing ST612-MRSA isolate in Western Australia is of the equine and veterinarian-associated ST612 clade.
- ST612 MRSA is closely-related to ST8 USA500 and carries conserved insertion sequences in virulence-modulating genes
- The use of rifampicin in equine veterinary practice may encourage colonization of horses by ST612.

Journal Prevention

# Multiple introductions of methicillin-resistant *Staphylococcus aureus* ST612 into Western Australia associated with both human and equine reservoirs

Riley JT Murphy<sup>1</sup>, Joshua P Ramsay<sup>1</sup>, Yung T Lee<sup>2</sup>, Stanley Pang<sup>2, 3</sup>, Mark A O'Dea<sup>2</sup>, Julie C Pearson<sup>3</sup>, Jane E Axon<sup>4</sup>, Edward Raby<sup>3</sup>, Shima M Abdulgader<sup>5</sup>, Andrew Whitelaw<sup>5, 6, 7</sup>, Geoffrey W Coombs<sup>2, 3</sup>

## Affiliations

<sup>1</sup>Curtin Health Innovation Research Institute (CHIRI) and School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Western Australia, Australia

<sup>2</sup>Antimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Western Australia, Australia

<sup>3</sup>Department of Microbiology, Fiona Stanley Hospital, PathWest Laboratory Medicine-WA, Western Australia, Australia

<sup>4</sup>Clovelly Intensive Care Unit, Scone Equine Hospital, 106 Liverpool Street, Scone, New South Wales, Australia

<sup>5</sup>Division of Medical Microbiology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Western Cape, South Africa

<sup>6</sup>Division of Medical Microbiology, Department of Pathology, Stellenbosch University, Western Cape, South Africa

<sup>7</sup>National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa

#### Abstract

*Staphylococcus aureus* is a serious human and animal pathogen. Multilocus sequence type 612 (ST612) is the dominant methicillin-resistant *S. aureus* (MRSA) clone in certain South African hospitals and is sporadically isolated from horses and horse-associated veterinarians in Australia. Colonization and infection by ST612-MRSA is increasing in Western Australia. Whole-genome sequencing was performed for 51 ST612-MRSA isolated from Western Australian patients and healthcare workers, South African hospital patients, Australian veterinarians and New South Wales horses. Core-genome phylogenies suggested Australian equine and veterinarian-associated ST612 were monophyletic. Individual Western Australian isolates grouped either with this equine-associated lineage or more diverse lineages related to those in South African hospitals. Bioinformatic analyses of the complete ST612-MRSA reference genome SVH7513 confirmed ST612-MRSA was closely related to ST8 USA500 MRSA. Common use of rifampicin in South Africa and equine veterinarian practice may favor ST612-MRSA in these settings. ST612-MRSA-colonized humans and horses are potential reservoirs for MRSA in Australia.

**Keywords:** Methicillin-resistant *Staphylococcus aureus*, zoonosis, equine, bacteremia, molecular epidemiology, MRSA

#### 1. Introduction

*Staphylococcus aureus* is a versatile and virulent opportunistic pathogen of humans and animals. The organism is increasingly resistant to multiple antimicrobials, which has led to reduced therapeutic options and increased morbidity and mortality. Emergence of methicillin-resistant *S. aureus* (MRSA) within hospitals has prompted increased surveillance and infection control measures. Since the 1990s MRSA has also been increasingly associated with infections acquired outside of the hospital environment and are referred to as community-associated MRSA (CA-MRSA). Although MRSA is associated with human hosts, MRSA carriage, infection and transmission, is also observed in domestic animals such as cats, dogs, horses, and livestock, such as pigs and cows. As such, animals may also act as MRSA reservoirs and may account in part for the rise of CA-MRSA [2].

Expansion of MRSA host range can be attributed to the acquisition of host-specific virulence and colonization factors carried by a variety of mobile genetic elements (MGEs) [3]. Multilocus sequence type 612 (ST612) is a member of clonal complex 8 (CC8), which includes the dominant USA CA-MRSA, USA300, and the closely related USA500 lineage [4]. Although ST612 MRSA is frequently identified in South Africa (SA) [5] where it is over-represented in bacteremia cases [6], it is not a frequently reported cause of human infections elsewhere. In Australia, ST612-MRSA has been isolated from veterinarians and from New South Wales (NSW) horses [7]. Furthermore ST612-MRSA is also increasingly detected in human patients living in Western Australia (WA), with at least one case leading to serious bacteremia [8]. In brief, ST612-MRSA was cultured from the nasal swab of a WA Patient 9. The isolate was resistant to co-trimoxazole, rifampicin, erythromycin and doxycycline. Within a year, the partner of WA Patient 9, WA Patient 1, had a bacteremia with ST612-MRSA. The couple had a close

association with horses. Here, we collected and analyzed the genome sequences of humanassociated ST612-MRSA from WA, NSW, South Australia and South Africa, along with horseassociated ST612-MRSA from NSW, in an attempt to identify potential origins of ST612-MRSA in WA.

#### 2. Materials and Methods

#### 2.1 Isolates

The ST612-MRSA (n = 51) isolates used in this study included: isolates from patients (n = 10) and healthcare workers (n = 3) living in WA; patient isolates from Tygerberg hospital (Cape Town, South Africa) (n = 8); isolates from the Scone Veterinary Hospital (Scone, NSW, Australia) isolated from horses (n = 24) and veterinarians (n = 3) [7]; and isolates from South Australian veterinarians attending a series of Australian veterinary conferences in 2009 (n = 3) (previously described, [9]). Isolate details are provided in appendix Table S1.

# 2.2 Genome sequencing and assembly

All isolates were grown in overnight cultures of tryptic soy broth media, with shaking at 37 ° C. Whole DNA extractions were performed as described previously [10]. Genomic DNA libraries were prepared using the Nextera XT Library Prep Kit (Illumina) and were sequenced on the Illumina MiSeq platform. Reads were cleaned, assembled and annotated using the Nullarbor bioinformatic pipeline software package (github.com/tseemann/nullarbor). Isolate SVH7513 from the Scone Veterinary Hospital collection, was sequenced using long-read SMRT-cell sequencing to produce a finished high-quality reference genome, as previously described [10]. Genome sequence assemblies have been deposited in Genbank under BioProject accession PRJNA558684.

2.3 Typing and identification of mobile genetic elements

Multi-locus sequence typing was performed with MLST v 2.10 (github.com/tseemann/mlst). *spa* and SCC*mec* typing were performed in silico using spaTyper 1.0 (https://cge.cbs.dtu.dk/services/spatyper) and SCCmecFinder (https://cge.cbs.dtu.dk/services/SCCmecFinder/) software, respectively. Plasmids were detected using PlasFlow [11]. Antimicrobial-resistance and virulence genes were detected using abricate (v 0.8, github.com/tseemann/abricate) to query the Resfinder (https://bitbucket.org/genomicepidemiology/resfinder\_db.git) and Virulence Factor Database (VFDB) databases, respectively. SaPI elements were identified manually with BLASTn by searching genomes for previously described att sites [12], while comparisons of SaPI were made with a BLASTn library of SaPI elements retrieved from Genbank (Table S2) and visualized in Ugene v1.3.

2.4 Comparison of genomes and phylogenetics

Reference ST612-MRSA genome SVH7513 (CP029166.1) was aligned with USA500 (CP007499) using BRIG (v 0.95, [13]), as were their associated plasmids pSVH7513a (CP029167.1) and pUSA500 (CP007500.1), respectively. Core-genome alignments were produced using Snippy v 3.2 (github.com/tseemann/snippy). Approximately-maximum-likelihood phylogenetic trees were computed using Fasttree v 2.1.10 [14] with the generalized-time reversible substitution model. Trees were visualized with the interactive Tree of life (iTol v 3, https://itol.embl.de/).

#### 3. Results

3.1 Genome composition of the ST612-MRSA reference genome SVH7513.

SVH7513, isolated from an Australian horse in 2008, was selected as a reference genome. Initial queries of the NCBI database confirmed SVH7513 was closely related to the ST8 strain USA500. The closest related USA500 strains were from CC8-USA500 clade I, the same clade as the USA500 clinical isolate reference genome 2395 USA500 [15, 16]. Whole-genome comparisons revealed SVH7513 and USA500 2395 (Accession CP007499) shared 99% identity and over 97% coverage of the genome. USA500 is a highly virulent hospital and CA-MRSA strain, whose virulence has been attributed to the modulation of virulence gene expression through the acquisition of insertion sequences (IS) within virulence-associated gene-regulatory regions. Sixteen copies of IS256 are found throughout the USA500 chromosome, while fourteen copies were found in the SVH7513 chromosome. Seven copies of IS256 were located in identical positions to those in USA500 2395 (Table S3), including a copy located upstream of the virulence-associated fibrinogen-binding gene *sdrD* and one copy interrupting the 'repressor of toxin' gene rot, which is attributed to the enhanced virulence of USA500 [16]. Of the seven unique IS256 disruptions in SVH7513, five were within intergenic regions, while two occurred within coding sequences for predicted genes with no homologues (Table S3). Sequence queries of SVH7513 and USA500 2395 genomes with the Virulence Factor Database revealed both lineages share the same number of known virulence-associated genes (n=68), including leukotoxin lukEv-lukDv and cytotoxin genes (hla, hld, and hlgABC). Like USA500, SVH7513 carried a Type IVd SCCmec element and a 27,887-bp multi-resistance plasmid dubbed pSVH7513a (CP029167), which was 99% identical (98% coverage) to pUSA500. pSVH7513a carried resistance genes for trimethoprim (*dfrC*), cadmium (*cadC*), aminoglycosides (*aac6-aph2*)

and beta-lactams (*blaZ*). Additionally, SVH7513 carried a small 2,496-bp plasmid, dubbed pSVH7513b (CP029165.1), which encoded the inducible erythromycin resistance gene *ermC* and *repL*-family rolling-circle replication initiation gene. USA500 2395 and SVH7513 shared several prophage and pathogenicity islands, including *hlb*-converting prophage  $\varphi$ SA3, which carried the human immune evasion genes *sak* and *scn* and enterotoxin *sea*, and the Staphylococcal Pathogenicity Island SaPI3, encoding enterotoxin genes *seb*, *selk* and *selq*. The SVH7513 genome was 40.3 kb smaller than the USA500 2395 genome, primarily due to variations within SaPI elements and prophage  $\varphi$ SA2 and the absence of prophage  $\varphi$ SA7. SVH7513 contained a previously unidentified SaPI, named here SaPIsvh7513 (Figure 1).

3.2 Sequencing and whole-genome comparisons of ST612-MRSA isolated from humans and horses in Australia and humans in South Africa.

To determine the origin of ST612-MRSA in WA, 51 ST612-MRSA genomes were sequenced with an average 56-fold depth of coverage. The majority of isolates 42/51 (82.3%) were *spa* type t064. The remaining isolates were t1257 (6/51=11.8%), t723 (2/51=3.9%) and a single t7571, all of which are closely related to t064, containing either insertions, rearrangements or deletions of *spa* repeat sequences. Overall, there was little variation of the core genome between ST612-MRSA genomes. All isolates harbored SCC*mec* IVd, *lukEv-lukDv* and carried a tetracycline-resistance gene (*tetM*) on an integrative and conjugative element (ICE) related to Tn5801, integrated at the 3' end of the GMP-synthase gene *guaA*. The isolates shared identical RNA polymerase subunit B (*rpoB*) genes, conferring rifampicin resistance (His481->Asn, Ile527->Met). All isolates carried pSVH7513a (described above), while the erythromycin-resistance plasmid pSVH7513b was sporadically present in 58.8% of isolates (30/51). The beta-lactamase

gene *blaZ* was present in all isolates, but was disrupted by an IS256 insertion in all but three isolates (NSW Horse 18 and 21, and South African Patient 4). Some resistance genes were present only sporadically, such as macrolide-streptogramin resistance (*msrA*, *n*=3), quaternary ammonium disinfectant resistance (*qacB*, *n*=1), chloramphenicol (*catA7*) and streptomycin (*str*) resistance (*n*=1). In two isolates, the loss of prophage  $\varphi$ SA3 resulted in the restoration of the βhemolysin gene, *hlb*. Two unique SaPIs were identified among the South African isolates, dubbed SaPItkn92 and SaPIthw70 (Figure 1). Differences in virulence-associated and antimicrobial resistance genes are depicted in Figure 2.

3.3 Equine-associated ST612-MRSA form a distinct clade and both human and equineassociated lineages are both possible sources of WA ST612-MRSA.

A Maximum-Likelihood phylogenetic tree was constructed using the core genomes of the 51 ST612-MRSA and represented a total of 3,988 single-nucleotide polymorphisms (SNPs) across a core genome of 2,915,384 bp. All horse and veterinarian-isolated ST612-MRSA grouped within a single clade together with several WA patient isolates (Figure 2). The greatest SNP differences were between WA Patient 2 and South African Patient 3 (n=134 bp), while the minimum number of SNP differences were between NSW Horses 16, 18 and 22 (n=0 bp) and NSW Horses 1 and 15 (n=0 bp). Five of the Western Australian human isolates grouped with the equine-associated clade, while the remaining eight clustered with various more diverse South African ST612-MRSA isolates.

#### 4. Discussion

This study aimed to identify the origins of ST612 in WA. Characterization of ST612-MRSA was performed by comparison with a high-quality ST612-MRSA genome and closely-related and well-characterized USA500 MRSA genome (Accession CP007499, [16]). Except for variation in prophage and SaPI, ST612-MRSA SVH7513 shared many MGEs and an identical suite of characterized virulence-associated genes.

'Hyper virulence' of USA500 has been attributed to the increased expression of virulence genes, mediated by chromosomal insertions of IS256. Many IS256 sites of USA500 were shared with SVH7513, including a copy inserted into the repressor of toxins gene, *rot*. The insertion of IS256 in *rot* results in increased toxin production, resulting in enhanced spleen colonization and survival in the presence of neutrophils [16]. Disruption of *rot* suggests SVH7513 may share a similar virulence-gene expression profile as the hyper-virulent USA500. Variations in IS256 distribution amongst ST612-MRSA genomes, such as the absence of a disruptive IS256 insertion in the *blaZ* genes of three isolates, as well as the different distributions of seven IS256 in SVH7513 relative to USA500, demonstrates the mobility of IS256 in these isolates.

The ST612-MRSA core-genome phylogeny was consistent with multiple introductions of ST612-MRSA into WA. The phylogenetic tree formed a single low-diversity clade containing all horse and veterinarian-associated ST612-MRSA along with several WA ST612-MRSA isolated from humans. The remainder of Western Australian and South African ST612-MRSA were relatively more diverse, but groupings suggested multiple exchanges of distinct ST612-MRSA. WA has a significant South African population (1.7% of the WA population, [*Population census*]

- *country of birth*, ABS 2016, [17]]), so the potential for direct introductions of ST612-MRSA from South Africa by travel is not unreasonable.

The monophyletic grouping of equine and veterinarian-isolated ST612-MRSA in this study is unsurprising, as previous studies have identified an increased risk of carriage of ST612 MRSA for equine veterinarians [9]. It is possible that this lineage of ST612-MRSA has adapted to persistently colonize horses and may therefore present a reservoir of MRSA for human infections. Indeed, the most serious case of ST612-MRSA infection in WA (WA Patient 1) occurred within a patient who had direct contact with horses, suggesting transmission of virulent ST612 MRSA to and from horses. However, we additionally sampled thirty-nine horses on the property of WA Patient 1 by nasal swab in March 2016 in an attempt to isolate ST612 MRSA, but no MRSA were detected. Thus, the source may have been a different stable, introduced for example from personnel working between stables or following interstate travel.

The equine and veterinarian-associated ST612-MRSA in this study were isolated in 2008-2009, while the most recent and likely zoonotic infection from a member of this clade occurred in 2016, suggesting ST612-MRSA has been circulating in Australian horse populations for at least seven years with little genetic change occurring during that time. The presence of genetically close ST612-MRSA in horses and humans, over a wide span of years and geographic range, suggests ST612-MRSA may have a combination of virulence factors and antimicrobial-resistance determinants that allow it to persist in at least one of these hosts. The equine-adaptation phage  $\Phi$ Saeq1 was not identified in any of the isolates here and therefore is not a requisite for the colonization or infection of horses. The presence of a  $\phi$ SA2-type prophage,

φSA2svh7513, and SaPIsvh7513, all of which encode genes of unknown functions within accessory gene regions, could contribute to equine host adaptation. The ability of ST612-MRSA to persist in South Africa and the Australian horse population however may be an unfortunate consequence of antimicrobial selection favoring ST612-MRSA. All ST612-MRSA in this study had an identical mutant rpoB gene, which provides constitutive rifampicin resistance. The mutations in the *rpoB* genes are consistent with those previously identified in ST612-MRSA from South Africa [5]. Additionally, all ST612-MRSA carried the trimethoprim-resistance plasmid pSVH7513a. Jansen van Rensburg et al (2011) [18] suggested the prevalence of ST612-MRSA in South Africa could be the result of selection by the use of rifampicin and trimethoprim/sulfamethoxazole. Rifampicin is used in South Africa for the treatment of tuberculosis [5], while trimethoprim/sulfamethoxazole is used prophylactically for the control of bacterial and *Pneumocystis* infections in HIV infected patients. Rifampicin is uncommonly prescribed in Australia with only 6,020 prescriptions recorded in 2015 by the national Prescribing Benefit Scheme as compared to 5.6 million prescriptions for the commonly prescribed antibiotic cephalexin [19]. However, Saputra et al [20] suggest the prevalence of rifampicin-resistant ST612-MRSA in Australian horses is the result of the treatment of foals with rifampicin, in combination with macrolides, in preventing *Rhodococcus equi* infections. Trimethoprim has been used in horses, orally, for the treatment of respiratory infections, which would further select for ST612-MRSA in Australian horses.

Our findings support current local policy of MRSA screening at time of hospital admission for patients recently treated in overseas health facilities, but a targeted campaign raising awareness among equine veterinarians may also be warranted. The zoonotic potential of ST612-MRSA also

raises the question of whether the problem could be greater in nations with larger populations of both HIV infection and domesticated horses.

#### Acknowledgments

The authors wish to acknowledge Matthew Power, Prof. Mike Bunce and Dr. Megan Coghlan of the Curtin TrEnD Laboratory for their patient guidance and sequencing expertise. The Gram-positive typing laboratory at Fiona Stanley Hospital for providing the Western Australian MRSA.

#### **Declarations**

**Funding:** JPR is the recipient of an Australian Research Council Future Fellowship [Project ID FT170100235] funded by the Australian Government (http://www.arc.gov.au/grants). Riley – thanks APA scholarship, Curtin University and School of Pharmacy and Biomedical Sciences for consumables funding.

Competing Interests: The authors have no conflicts of interest to report

Ethical Approval: Not required.

#### References

[1] Walther B, Wieler LH, Friedrich AW, Hanssen AM, Kohn B, Brunnberg L, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA) isolated from small and exotic animals at a university hospital during routine microbiological examinations. Vet Microbiol. 2008;127:171-8.

[2] Cuny C, Wieler LH, Witte W. Livestock-Associated MRSA: The Impact on Humans. Antibiotics (Basel). 2015;4:521-43.

[3] Richardson EJ, Bacigalupe R, Harrison EM, Weinert LA, Lycett S, Vrieling M, et al. Gene exchange drives the ecological success of a multi-host bacterial pathogen. Nature ecology & evolution. 2018;2:1468-78.

[4] Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, et al. Evolution of virulence in epidemic community-associated methicillin-resistant *Staphylococcus aureus*. Proc Natl Acad Sci U S A. 2009;106:5883-8.

[5] Jansen van Rensburg MJ, Whitelaw AC, Elisha BG. Genetic basis of rifampicin resistance in methicillinresistant *Staphylococcus aureus* suggests clonal expansion in hospitals in Cape Town, South Africa. BMC Microbiol. 2012;12:46.

[6] Perovic O, Iyaloo S, Kularatne R, Lowman W, Bosman N, Wadula J, et al. Prevalence and Trends of *Staphylococcus aureus* Bacteraemia in Hospitalized Patients in South Africa, 2010 to 2012: Laboratory-Based Surveillance Mapping of Antimicrobial Resistance and Molecular Epidemiology. PLoS One. 2015;10:e0145429.

[7] Axon JE, Carrick JB, Barton MD, Collins NM, Russell CM, Kiehne J, et al. Methicillin-resistant *Staphylococcus aureus* in a population of horses in Australia. Aust Vet J. 2011;89:221-5.

[8] Raby E, Coombs GW, Pang S, Pearson J, Robinson OJ, Dyer J. Zoonotic transmission of the methicillinresistant *Staphylococcus aureus* ST612-IV equine strain. Break Point Newsletter: Australian Society for Antimicrobials; 2016. p. 4-6.

[9] Groves MD, Crouch B, Coombs GW, Jordan D, Pang S, Barton MD, et al. Molecular Epidemiology of Methicillin-Resistant *Staphylococcus aureus* Isolated from Australian Veterinarians. PLoS One. 2016;11:e0146034.

[10] Murphy RJT, Lee YT, Pang S, Bastholm TR, Crow JE, Davis AM, et al. Complete Genome Sequence of a *Staphylococcus aureus* Sequence Type 612 Isolate from an Australian Horse. Microbiol Resour Announc. 2018;7.

[11] Krawczyk PS, Lipinski L, Dziembowski A. PlasFlow: predicting plasmid sequences in metagenomic data using genome signatures. Nucleic acids research. 2018;46:e35.

[12] Novick RP, Ram G. Staphylococcal pathogenicity islands-movers and shakers in the genomic firmament. Current opinion in microbiology. 2017;38:197-204.

[13] Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons. BMC Genomics. 2011;12:402.

[14] Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5:e9490.

[15] Frisch MB, Castillo-Ramirez S, Petit RA, 3rd, Farley MM, Ray SM, Albrecht VS, et al. Invasive Methicillin-Resistant *Staphylococcus aureus* USA500 Strains from the U.S. Emerging Infections Program Constitute Three Geographically Distinct Lineages. mSphere. 2018;3:e00571-17.

[16] Benson MA, Ohneck EA, Ryan C, Alonzo F, 3rd, Smith H, Narechania A, et al. Evolution of hypervirulence by a MRSA clone through acquisition of a transposable element. Mol Microbiol. 2014;93:664-81.


[17] 2016 Census of Population and Housing Western Australia. In: Statistics ABo, editor.2016.

[18] Jansen van Rensburg MJ, Eliya Madikane V, Whitelaw A, Chachage M, Haffejee S, Gay Elisha B. The dominant methicillin-resistant *Staphylococcus aureus* clone from hospitals in Cape Town has an unusual genotype: ST612. Clin Microbiol Infect. 2011;17:785-92.

[19] Mabbott V, Storey P. Australian Statistics on Medicines. Australian Government, Department of Health; 2015.

[20] Saputra S, Jordan D, Worthing KA, Norris JM, Wong HS, Abraham R, et al. Antimicrobial resistance in coagulase-positive staphylococci isolated from companion animals in Australia: A one year study. PLoS One. 2017;12:e0176379.


Journal



**Figure 1.** Unique SaPI elements found in ST612 genomes. BLASTn matches represent regions of >95% nucleotide identity to the indicated SaPI elements. SaPIsvh7513 and SaPIthw70 both integrate into the 30S ribosomal S18 gene, while SaPItkn92 has displaced Tn*5801* at the *guaA* GMP synthase gene site. Distribution of these SaPI among ST612 isolates is indicated in Figure 2.

lonu an

**Tables and Figures** 



**Figure 2.** Maximum-Likelihood phylogenetic tree of core genomes from 43 Australian and 8 South African ST612 *S. aureus.* Isolate names indicate origins of the represented genomes: NSW (New South Wales), WA (Western Australian), SA (South Australian), and SAFRICA (South African). HCW denotes a healthcare worker. Year of isolation (Date) and *spa* type are shown. Scale bar indicates average substitutions per site. Presence of resistance and virulence genes, prophage and SaPI is indicated by filled squares. Names of associated mobile genetic elements are bracketed if known.